Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance

American Journal of Hematology

Volumn 85, Issue 5, 2010, Pages 396-

  Ojeda Uribe, Mario ^a   Caron, Claudine ^b   Itzhar Baikian, Nathalie ^c   Debliquis, Agathe ^a  

^a Hôpitaux Universitaires de Strasbourg   (France)

^b UNIV LILLE   (France)

^c HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BORTEZOMIB; CALCIUM; CREATININE; DEXAMETHASONE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RITUXIMAB;

ADULT; CASE REPORT; DISEASE ASSOCIATION; HUMAN; LETTER; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTHROMBIN TIME; UREA NITROGEN BLOOD LEVEL; VON WILLEBRAND DISEASE;

EID: 77951539344     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21692     Document Type: Letter

References (6)

1. Mohri H. Acquired von Willebrand syndrome: Features and management. Am J Hematol 2006;81:616-623. (Pubitemid 44066172)
2. Kumar S, Pruthi RK, Nichols W. Acquired von Willebrand Disease. Mayo Clin Proc 2002;77:181-187.
3. Kyle RA, Themeau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362-1369.
4. Grimaldi D, Bartolucci P, Gouault-Hellmann M, et al. Rituximab failure in a patient with monoclonal gammopathy of undetermined significance (MGUS)-associated acquired vonWillebrand syndrome. Thromb Haemost 2008;99:782-783. (Pubitemid 351694237)
5. Mazoyer E, Fain O, Dhote R, Laurian Y. Is rituximab effective in acquired von Willebrand syndrome? Br J Haematol 2009;144:967-968.
6. Siaka C, Rugeri L, Caron C, Goudemand J. A new ELISA assay for diagnosis of acquired von Willebrand Syndrome. Haemophilia 2003;9:303-308. (Pubitemid 36622033)